Regeneron Pharmaceuticals And Sanofi Announce Sustained Efficacy Of Dupixent® (dupilumab) Phase 3 Results In Children Aged 1 To 11 With Eosinophilic Esophagitis For Up To One Year
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals and Sanofi have announced sustained efficacy of Dupixent (dupilumab) Phase 3 results in children aged 1 to 11 with Eosinophilic Esophagitis for up to one year. The data presented at ACG 2023 showed maintained histologic and endoscopic improvements with no new safety signals. The sBLA for Dupixent to treat children with EoE is under Priority Review in the U.S. If approved, Dupixent would be the first and only FDA-approved treatment for these children.
October 23, 2023 | 6:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's Dupixent shows promising Phase 3 results, potentially becoming the first FDA-approved treatment for children with EoE. This could boost the company's market position and revenues.
The positive Phase 3 results and the potential FDA approval for Dupixent could significantly impact Regeneron's stock. The drug's approval would open a new market for the company, potentially increasing its revenues and boosting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sanofi, as a partner in the development of Dupixent, stands to benefit from the positive Phase 3 results and potential FDA approval. This could enhance its product portfolio and revenues.
Sanofi, being a partner in the development of Dupixent, could see a positive impact on its stock due to the promising Phase 3 results. If the drug is approved by the FDA, it would strengthen Sanofi's product portfolio and could lead to increased revenues, positively affecting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100